Novavax Inc (NASDAQ:NVAX) has grabbed attention from the analysts, when it saw a value decrease of -12.33% or -0.81 points in the last trading session to close at $5.76. A total of 1.19 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 902.23 Million shares, while its relative volume stands at 1.32. Novavax Inc (NASDAQ:NVAX) has a market cap of $2.7 Billion and the number of outstanding shares have been calculated 469.45 Million.

Shares of Novavax Inc (NASDAQ:NVAX) currently have an Average Brokerage Recommendation of 2, number of Recs in ABR is 6 while industry rank of the company by ABR is out of 256. Out of the analyst recommendations 3 rate Novavax Inc (NASDAQ:NVAX) stock a Buy, 2 rate the stock Outperform, 2 rate Hold, 1 rate Underperform and 0 recommend a Sell.

Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $1.42 on the stock, this valuation is based on 7 number of opinions. The most optimistic analyst sees the stock reaching $2 while the most conventional has $0.5 target price.

Novavax Inc (NASDAQ:NVAX) as of recent trade, has shown weekly downbeat performance of -37.58% which was maintained at -49.23% in 1-month period. During the past three months the stock slid -86.91%, bringing six months performance to -85.38%. Yearly performance of the stock shows a bearish trend of -82% while year-to-date (YTD) performance reflected -84.35% negative outlook.

While taking a glance at financials, we can look at a number of key indicators. Novavax Inc (NASDAQ:NVAX) has trailing twelve month Return on Assets of 0%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of 0% and a Return on Investment of 0%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.

While having a peek at profitability ratios Novavax Inc (NASDAQ:NVAX) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%.

However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 0. Novavax Inc (NASDAQ:NVAX)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at 0.

The company’s quick ratio for most recent quarter is 0 along with current ratio for most recent quarter of 0. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.